echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Several well-known pharmaceutical companies are sold.

    Several well-known pharmaceutical companies are sold.

    • Last Update: 2020-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the announcement, Shaanxi Friends Gang is a wholly-owned subsidiary of Shandong Friends Gang, which is currently under construction and is expected to be put into operation by the first half of 2021 at the latest, with the main products including: antimicrobial intermediates, anti-cancer drug intermediates, antiviral drug intermediates, cardiovascular and cerebrovascular drug intermediates, etc.
    , four pharmaceutical intermediate workshop, three equipment storage buildings, research and development, the main body of the administrative building has been completed.
    construction is successful, it is expected that the Nos. 1 and 2 pharmaceutical intermediates workshop will be put into operation by the end of June 2021.
    the completion of the 1st and 2nd pharmaceutical intermediate workshop, the main plan is to produce oxygen cephalosporine and 7ANCA products, these two products are mainly used in the production of cephalosporin products.
    oxygen cephalosporine and 7ANCA in China by the process, safety, environmental protection and other factors, so far mainly rely on imports, the future, with the two products in Shaanxi You gang put into production, will bring good economic benefits to Kanghui Pharmaceutical.
    can be seen that the purpose of this Kanghui pharmaceutical acquisition is to supplement their own API production pipeline, which is currently the major domestic pharmaceutical companies are in the field of active layout.
    , especially some highly imported API and intermediates, can easily affect the price of imported medicines.
    many pharmaceutical companies are in advance layout, early lock costs, so that enterprises can largely hedge the volume of procurement brought about by the impact of drug price reduction.
    , consistency evaluation also improved the quality requirements of API, the importance of API immediately increased.
    , the integration of API preparations will occupy the initiative in cost, price, age and so on, which is also the trend of industry development.
    the acquisition of GNC, or loss of more than 2 billion yuan on September 22, the company issued a notice to disclose the latest developments on GNC-related matters.
    local court has approved and authorized the parties to advance the GNC sale plan in accordance with the relevant transaction documents, the company said in a statement.
    fact, on September 18th, the company announced that on September 17th, EST, the U.S. Bankruptcy Court had approved GNC's $770 million sale of assets to the group.
    , the verdict has not yet been made public and still needs high court approval.
    company has not been able to determine the impact of the matter on the upfront subscription of Health and Safety's convertible preferred shares.
    pharmaceutical group said there was uncertainty about whether the deal would be completed.
    even if the deal can be completed, there are no plans to bring the company into the company in the short term.
    , the company's health care products business and health care business layout location and category are different, will not lead to competition in the industry.
    GNC, the company aims to introduce more advanced and excellent health care products to meet the growing health needs of consumers.
    as early as 2018, ha pharmaceutical shares paid $100 million to GNC for the equivalent of a 40.1% stake in GNC to promote, distribute, sell and import GNC products exclusively and localize the production of GNC products at Chinese mainland.
    GNC experienced a sharp drop in operating results in the first quarter, with about 40 percent of its 1,300 stores temporarily closed and the possibility of a permanent closure.
    , GNC entered the U.S. bankruptcy law restructuring process, and the investment of harpoon shares was also of concern.
    on June 24th, the company said in a statement that once it entered the Chapter 11 restructuring process of the U.S. bankruptcy law, the company, as a preferred shareholder, would not be able to get a priority settlement after ordinary creditors in the order of repayment, with losses of up to $2 billion.
    Domestic and foreign pharmaceutical mergers and acquisitions frequent this year, whether domestic pharmaceutical companies or multinational pharmaceutical enterprises, mergers and acquisitions between enterprises are very frequent, they are divestiture of non-core business "slim", but also through the acquisition of rich corporate layout of the product areas.
    september alone, there have been a number of drug mergers and acquisitions.
    September 21, Inflazome announced that it had reached a share purchase agreement with Roche and that Inflazome shareholders had received an advance of 380 million euros and were eligible for additional milestone payments.
    acquisition gives Roche full rights to Inflazome's entire product portfolio, which consists of clinical and preclinical oral small molecule NLRP3 inhibitors.
    Inflazome has a combination of small molecule NLRP3 inhibitors that can be taken or mouth, and the lead compound has successfully completed Phase 1 clinical trials.
    plans to further develop NLRP3 inhibitors in a variety of adaptations with highly unsuperfected medical needs.
    September 21, Shandong Step Pharmaceuticals announced that Shandong Step Pharmaceuticals has agreed to transfer a 51% stake in its controlling subsidiary, Hubei Step Chang Kyushua Pharmaceutical Co., Ltd., to Kyushua Tong Pharmaceutical Group Co., Ltd. for 2.1752 million yuan.
    , Hubei Province, has completed the registration of industrial and commercial changes, and obtained the Hubei Provincial Market Supervision Bureau issued a "business license."
    with the completion of industrial and commercial changes in Kyushua, Hubei Step Pharmaceuticals completely divested the pharmacy business.
    September 13th Gilead announced that it would buy Immunomedics, a US biotech company, for $88 a share in cash.
    public information, Immunomedics is a pioneer in the next generation of antibody drug coupleds (ADCs).
    April, Trodelvy, the company's first commercial ADC product, received accelerated FDA approval for adult patients with metastasis triple negative breast cancer who had previously received at least two treatments for metastasis.
    CEO Daniel O'Day said the deal will help Gilead accelerate its efforts to diversify into the cancer sector.
    September 10, Kang Yue Technology announced that it intends to acquire a 52.75 percent stake in Changjiang Star Pharmaceutical Co., Ltd. of Changjiang Chain, Caitong Capital and Wang Dongxiang for 1,414 million yuan in cash.
    Through this acquisition, Kang Yue Technology entered the pharmaceutical industry such as Chinese medicine tablets, medical hollow capsules and pharmaceutical wholesale.
    September 1, Haizheng Pharmaceuticals announced that it intends to buy a 49% stake in HPPC for 4.4 billion yuan.
    the acquisition, Hanyu Pharmaceuticals had a 5% stake in Haizheng Pharmaceuticals, 46% in Haizheng Pharmaceuticals (Hangzhou) Co., Ltd., and the remaining 49% in HPPC.
    if the acquisition is completed, Haizheng will own 100% of Hanyu Pharmaceuticals.
    we can also see that in recent years, domestic pharmaceutical companies and multinational pharmaceutical companies large-handed "buy and buy" situation is not uncommon.
    with the expiration of patents of multinational pharmaceutical companies, new drug research and development difficulties increase, the transformation into a way out, some increase investment in biomedicine, and some directly through mergers and acquisitions to make up for their own short board.
    In the domestic pharmaceutical enterprises, with the tax reform, as well as consistent evaluation, with the continuous promotion of volume procurement, many policies under the multiple effects of the pharmaceutical enterprises in the reshuffle, the concentration of domestic pharmaceutical enterprises will be further improved.
    process, most small and medium-sized pharmaceutical enterprises will not disappear, but through mergers and reorganization and other ways into large pharmaceutical enterprises.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.